Jpmorgan Chase & CO Next Cure, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Next Cure, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 807 shares of NXTC stock, worth $782. This represents 0.0% of its overall portfolio holdings.
Number of Shares
807
Previous 806
0.12%
Holding current value
$782
Previous $1,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding NXTC
# of Institutions
44Shares Held
15.9MCall Options Held
0Put Options Held
0-
Sofinnova Investments, Inc. Menlo Park, CA2.67MShares$2.59 Million0.35% of portfolio
-
Logos Global Management LP San Francisco, CA2.5MShares$2.43 Million0.45% of portfolio
-
Affinity Asset Advisors, LLC New York, NY2.3MShares$2.23 Million0.54% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.14MShares$1.11 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA987KShares$957,7040.0% of portfolio
About NextCure, Inc.
- Ticker NXTC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,748,800
- Market Cap $26.9M
- Description
- NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...